文献速递白血病淋巴瘤

阿可替尼联合高频低剂量皮下注射利妥昔单抗用于慢性淋巴细胞白血病初始治疗

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2023-01-01

这项II期研究纳入38例初治慢性淋巴细胞白血病患者,评估阿可替尼联合高频低剂量皮下利妥昔单抗(50 mg每周两次,共6个28天周期)的疗效与耐受性。所有患者均应答,其中1例在12个月时达到外周血和骨髓微小残留病灶阴性的完全缓解并停止治疗。中位随访2.3年时,2例具有高危特征的患者在阿可替尼单药治疗期间出现疾病进展。作者认为该方案有效、可耐受且可居家自行给药,为固定疗程治疗提供了平台。

要点

  • 38例初治慢性淋巴细胞白血病患者接受阿可替尼联合高频低剂量皮下利妥昔单抗治疗,所有患者均应答。
  • 1例患者在12个月时达到外周血和骨髓微小残留病灶阴性的完全缓解并停止治疗。
  • 中位随访2.3年时,2例具有高危特征的患者在阿可替尼单药治疗期间出现疾病进展。

核心结论

  • 高频低剂量利妥昔单抗联合阿可替尼是一种有效、可耐受、可居家自行给药的组合,为可能更可靠地实现固定疗程治疗的方案提供了平台。

研究设计与样本

  • II期研究,纳入38例初治慢性淋巴细胞白血病患者,评估阿可替尼联合高频低剂量皮下利妥昔单抗(50 mg每周两次,共6个28天周期,阿可替尼自第2周开始加用)的疗效与耐受性。
  • 患者在阿可替尼治疗12或24个周期后达到微小残留病灶阴性的完全缓解者可停止治疗。
  • 该试验在www.clinicaltrials.gov注册,注册号为NCT03788291。

主要发现

  • 所有患者均应答,包括1例在12个月时达到外周血和骨髓微小残留病灶阴性的完全缓解并停止治疗的患者。
  • 中位随访2.3年时,2例具有高危特征的患者在阿可替尼单药治疗期间出现疾病进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bruton tyrosine kinase inhibitors are an effective therapeutic agent for previously untreated patients with chronic lymphocytic leukemia but require indefinite treatment that can result in cumulative toxicities. Novel combinations of agents that provide deep remissions could allow for fixed duration therapy. Acalabrutinib, unlike ibrutinib, does not inhibit anti-CD20 monoclonal antibody-dependent cellular phagocytosis, making it a suitable partner drug to rituximab. Using standard dosing (375 mg/m2) of rituximab causes loss of target membrane CD20 cells and exhaustion of the finite cytotoxic capacity of the innate immune system. Alternatively, using high-frequency, low-dose (HFLD), subcutaneous rituximab limits loss of CD20 and allows for self-administration at home. The combination of HFLD rituximab 50 mg administered twice a week for 6 cycles of 28 days with the addition of acalabrutinib starting in week 2 was evaluated in a phase II study of 38 patients with treatment naive chronic lymphocytic leukemia. Patients achieving a complete response with undetectable minimal residual disease after 12 or 24 cycles of acalabrutinib could stop therapy. All patient responded, including one with a complete response with undetectable minimal residual disease in the peripheral blood and bone marrow at 12 months who stopped therapy. At a median follow-up of 2.3 years 2 patients with high-risk features have progressed while on acalabrutinib monotherapy. We conclude that HFLD rituximab in combination with acalabrutinib is an effective and tolerable self-administered home combination that provides a platform to build upon regimens that may more reliably allow for fixed-duration therapy. This trial was registered at www.clinicaltrials.gov #NCT03788291.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wallace DS, Zent CS, Baran AM, et al. Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia. Blood Adv. 2023. PMID: 36689726. doi:10.1182/bloodadvances.2022009382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。